Articles On Creso Pharma (ASX:CPH)

Creso Pharma Ltd (ASX:CPH | OTC:COPHF) has just confirmed two consecutive quarters of record revenue growth. CPH posted $1.71M revenue this quarter - up from $1.38M in the previous quarter - that’s 24% growth.

The Creso Pharma Ltd (ASX: CPH) share price has returned from its trading halt and stormed higher. At one stage today, the cannabis and psychedelics company’s shares were up as much as 21% to 17 cents. However, the Creso Pharma share price...

Creso Pharma Limited (ASX:CPH, FRA: 1X8) through its Swiss operations and wholly-owned Canadian subsidiary, Mernova Medicinal Inc. has achieved record sales growth for the June quarter. This has added to the company’s growing revenue profil...

Australian shares appeared to shrug off the latest COVID-19 lockdowns for much of the day, but ultimately closed lower on the day. The ASX200 finished 0.01 per cent down at 7,307, while the ASX Emerging Companies Index fell 1.22 per cent, c...

Around 1 million residents of some inner-Sydney suburbs are to stay at home until next Friday, after the latest government-imposed lockdown. The restrictions will begin at midnight today, and last until midnight on Friday, July 2. To market...

Last week, Creso Pharma Limited (ASX:CPH, FRA:1X8, OTC:COPHF) announced that it plans to merge its business with Red Light Holland Corp (CSE:TRIP, FRA:4Yx, OTC Pink:TRUFF) to become The HighBrid Lab. Following much shareholder speculation,...

The Althea Group Holdings Ltd (ASX: AGH) share price has been a positive performer on Wednesday. In early trade, the cannabis company’s shares are up 4.5% to 33.5 cents. Why is the Althea share price on a high today? Investors have been bu...

Today Creso Pharma (ASX: CPH | OTC: COPHF) announced its plans to merge with a Canadian listed psychedelics company called Red Light Holland.

The ASX plummeted into the red today despite positive jobs data out of the ABS, which showed unemployment falling for the seventh straight month to 5.1% while 115,000 jobs were added. This job growth was offset by the growing COVID outbreak...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading day. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intrad...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) has run out of steam and is trading lower. At the time of writing, the benchmark index is down 0.25% to 7,368.8 points. Four ASX shares that are falling more than most today are list...

The merger with Red Light Holland will form a new company called The HighBrid Lab, which will be listed in Canada. In a significant new development, global medicinal cannabis company, Creso Pharma (ASX:CPH), is gearing up to merge its busin...

The Creso Pharma Ltd (ASX: CPH) share price is sinking on Thursday after announcing merger plans. In morning trade, the cannabis and psychedelics company’s shares are down 5.5% to 17 cents. Why is the Creso Pharma share price sinking? Inve...

A merger announced today between Creso Pharma (ASX: CPH) and Canada's Red Light Holland (CSX: TRIP) will double the value of the former and create a global psychedelics and cannabis company called The HighBrid Lab. Under the agreement, Cr...

Creso Pharma Limited (ASX:CPH, FRA:1X8, OTC:COPHF), a developer of cannabis, hemp-derived therapeutic, nutraceuticals and lifestyle products has entered into a definitive agreement to merge its business with Red Light Holland Corp (CSE:TRIP...

The US cannabis sector received a big lift after Amazon announced that job applicants at its offices and warehouses will no longer be drug-tested for marijuana use. Delivery drivers, however, will still be tested. The company also said it w...

The ASX climbed briefly past 7,400 points in intra-day trade but ultimately closed just short of the milestone at 7,.368, which was 0.09 per cent higher than yesterday. However, the ASX Emerging Companies Index fell by over 1 per cent for t...

Summary The ASX 200 traded higher in the opening trade even as the US shares ended lower overnight. By 10:30 AM (AEST), the benchmark was trading at 7,391.50, up 0.16%. The US investors awaited the Federal Reserve’s monetary policy st...

Shares in Creso Pharma (ASX:CPH) have successfully listed on the US OTC market, with the stock finishing up 26% on its opening price. The OTCQB listed stock ended its first day of trading at 16.98 US cents equivalent to 22 Australian cents...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading day. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intrad...

The Creso Pharma [ASX:CPH] share price jumped 12% after the pot stock completed its US OTC dual listing. The post Creso Share Price Soars on US Dual Listing (ASX:CPH) appeared first on Money Morning Australia.

Creso Pharma Ltd (ASX:CPH) announced today that it has successfully completed a dual listing in the US and will commence trading in the region when the market opens US time (around 7.30pm this evening AEST). The company is trading on the US...

Creso Pharma (ASX:CPH) today announced its listing in the US, and the market is opening in around 12 hours - the US pool of investors is huge and they have a big appetite for psychedelics and cannabis stocks.

The listing will provide Creso Pharma access not only to deeper capital markets, but also the rapidly-growing North American cannabis sector. The long-awaited dual listing of Creso Pharma (ASX:CPH) shares in the United States is finally hap...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

Creso Pharma’s (ASX: CPH) Canadian acquisition target Halucenex Life Sciences has expanded the recruitment of a phase II clinical trial of psychedelic psilocybin to include non-veteran sufferers of treatment-resistant post-traumatic stress...

The Creso Pharma [ASX:CPH] share price rose today after acquisition target Halucenex expands clinical trial recruitment. The post Creso Share Price Up on Expanded Clinical Trial Plans (ASX:CPH) appeared first on Money Morning Australia.

Creso Pharma Limited’s (ASX:CPH; FRA: 1X8) targeted acquisition company Halucenex Life Sciences has made the strategic decision to expand the recruitment of its phase II clinical trial to include participants that have not served in the mil...

Creso Pharma (ASX:CPH) says the Canadian psychedelic research company it has agreed to acquire will broaden the scope of its upcoming clinical trial evaluating “magic mushrooms” as a post-traumatic stress disorder (PTSD) treatment. Halucene...

The Creso Pharma Ltd (ASX: CPH) share price has been a strong performer this morning. At the time of writing, the cannabis and psychedelics company’s shares are up 6% to 17 cents. This means the Creso share price is now up 16% since this t...

Creso Pharma (ASX: CPH) has expanded a distribution agreement with Route 2 Pharm Pvt Ltd that will see Creso’s hemp-based products sold in Ecuador as a starting point into the lucrative Latin American cannabis market. The deal follows an in...

The Creso Pharma Ltd (ASX: CPH) share price is on form again on Friday morning. At the time of writing, the cannabis and psychedelics company’s shares are up 5.5% to 19.2 cents. This means the Creso share price is now up a massive 35% in th...

Creso Pharma Limited (ASX:CPH, FRA: 1X8) is set to take its product deeper into the Latin American market. The expansion of its comprehensive distribution agreement with leading nutritional supplements company Route2 Pharm Pvt Ltd, will all...

There was plenty of action in the US regulatory front within the cannabis sector this week. A couple of major legislations during the week could potentially shake up the US cannabis industry. The Marijuana Opportunity Reinvestment and Expun...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading day. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intrad...

Historic shifts in legislation involving psychedelic use in the US could expedite market entry for Creso Pharma and its acquisition target.

The new California bill will open the market for Creso’s psychedelic products as it aims to become a first mover in the sector. Global medicinal cannabis company, Creso Pharma (ASX:CPH), is gearing up to enter the Californian market, follow...

A proposed bill to decriminalise the possession and sharing of psychedelic drugs in California has seen Creso Pharma (ASX: CPH) and its acquisition target Halucenex expedite a market entry strategy for psilocybin compounds as an alternative...

The Creso Pharma Ltd (ASX: CPH) share price is shooting higher on Thursday following a positive development. In morning trade, the cannabis and psychedelics company’s shares are up 11% to 15.5 cents. Why is the Creso share price shooting hi...

In what is a major development for Creso Pharma (ASX:CPH), target acquisition company Halucencex Life Sciences is fast tracking its go to market strategy in California. The decision was made to expedite a Californian market entry following...

–The below is a company-sponsored announcement– At the start of 2021, the first six ASX-listed companies began improving their Environmental, Social and Governance (ESG) credentials and reporting their progress against the World Economic...

At the start of 2021, the first six ASX-listed companies began improving their Environmental, Social and Governance (ESG) credentials and reporting their progress against the World Economic Forum’s 21 universal ESG metrics, using “ESG on-ra...

The US legalisation movement took another big step forward last week, after lawmakers elected to reintroduce the Marijuana Opportunity Reinvestment and Expungement (MORE) Act to Congress, which would eliminate the federal ban on cannabis....

Halucenex will pursue FDA approval for botanical psilocybin products and commence licensing discussions with large pharma in preparation for a potential US market launch.

In an important commercial development, Creso Pharma Limited’s (ASX:CPH, FRA:1X8) target acquisition company Halucenex Life Sciences Inc. has entered into a consultancy agreement with leading US-based scientific consultancy HeteroGeneity, L...

Creso Pharma’s (ASX: CPH) soon-to-be-subsidiary Halucenex Life Sciences Inc has inked a deal with US-based scientific consultancy HeteroGeneity LLC to progress a US market entry strategy for its range of botanical psilocybin products and co...

The agreement with Polvet Healthcare Teodorowski Spółka Jawna broadens CPH’s footprint in Europe and marks the company’s first entry into Eastern Europe.

It has been a big week for Creso Pharma (ASX:CPH). This week the company made three important announcements: Wholly owned subsidiary Mernova Medicinal Inc. was awarded Craft Designation by the Ontario Cannabis Store (OCS). CPH has finalise...

In 2021, which of Europe and North America is the place to be for ASX cannabis stocks?   The case for Europe A few years ago there would’ve been no question that it was North America with Canada legalising recreational cannabis as well as h...

The launching of an Anibidiol product for pigs today has expanded Creso’s product range and gives the company access into the lucrative livestock market. Global medicinal cannabis company, Creso Pharma (ASX:CPH), is about to enter the lives...